Cargando…

A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer

BACKGROUND: Prostate cancer (PCa), a prevalent malignant cancer in males worldwide, screening for patients might benefit more from immuno-/chemo-therapy remained inadequate and challenging due to the heterogeneity of PCa patients. Thus, the study aimed to explore the metabolic (Meta) characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, He, Gu, Jie, Tian, Yuqiu, Li, Shuyu, Zhang, Hao, Dai, Ziyu, Wang, Zeyu, Zhang, Nan, Peng, Renjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620963/ https://www.ncbi.nlm.nih.gov/pubmed/36325340 http://dx.doi.org/10.3389/fimmu.2022.982628

Ejemplares similares

Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma
por: Wang, Qi, et al.
Publicado: (2022)

Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer
por: Zhang, Hao, et al.
Publicado: (2021)

SLC7A11, a potential immunotherapeutic target in lung adenocarcinoma
por: Shan, Qingqing, et al.
Publicado: (2023)

SLC25A11 serves as a novel prognostic biomarker in liver cancer
por: Pan, Guoqiang, et al.
Publicado: (2020)

SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
por: Zhang, Pei, et al.
Publicado: (2023)

A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma
por: Liu, Jin, et al.
Publicado: (2022)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential
por: Xiong, Jie, et al.
Publicado: (2021)

Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma
por: Zheng, Bohao, et al.
Publicado: (2023)

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Liang-Hao, et al.
Publicado: (2021)

Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response
por: Chen, Rui, et al.
Publicado: (2022)

P338: SLC7A11 PROMOTES ARGININE BIOSYNTHESIS IN ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMMUNOTHERAPEUTIC POTENTIAL
por: LI, Jiazheng, et al.
Publicado: (2023)

Corrigendum: Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response
por: Chen, Rui, et al.
Publicado: (2022)

SLC17A9 expression levels in a pan‑cancer panel and validation of the role of SLC17A9 as a novel prognostic biomarker for osteosarcoma
por: Li, Junqing, et al.
Publicado: (2023)

Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature
por: Zhang, Chunyu, et al.
Publicado: (2021)

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer
por: Chen, Jiang, et al.
Publicado: (2022)

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
por: Wang, Tao, et al.
Publicado: (2022)

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
por: Chen, Hongquan, et al.
Publicado: (2022)

Corrigendum: Immunogenomic landscape in breast cancer reveals immunotherapeutically relevant gene signatures
por: Wang, Tao, et al.
Publicado: (2023)

Optimal subset of signature miRNAs consisting of 7 miRNAs that can serve as a novel diagnostic and prognostic predictor for the progression of cervical cancer
por: Shi, Can, et al.
Publicado: (2019)

An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms
por: Zhang, Nan, et al.
Publicado: (2023)

Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment
por: Zhang, Nan, et al.
Publicado: (2021)

Metabolism-Related Signature Analysis Uncovers the Prognostic and Immunotherapeutic Characteristics of Renal Cell Carcinoma
por: Zhang, Jianye, et al.
Publicado: (2022)

Identification of Lactate-Related Gene Signature for Prediction of Progression and Immunotherapeutic Response in Skin Cutaneous Melanoma
por: Xie, Yalin, et al.
Publicado: (2022)

A Novel Prognostic Signature Associated with Immunotherapeutic Response for Hepatocellular Carcinoma
por: Jin, Xinmin, et al.
Publicado: (2022)

Tumor microenvironment characterization in head and neck cancer identifies prognostic and immunotherapeutically relevant gene signatures
por: Huo, Mengqi, et al.
Publicado: (2020)

Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Lianghao, et al.
Publicado: (2021)

Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication
por: Sun, Sijin, et al.
Publicado: (2021)

Five-gene signature associating with Gleason score serve as novel biomarkers for identifying early recurring events and contributing to early diagnosis for Prostate Adenocarcinoma
por: Zhang, Lingyu, et al.
Publicado: (2021)

SLC13A4 Might Serve as a Prognostic Biomarker and be Correlated with Immune Infiltration into Head and Neck Squamous Cell Carcinoma
por: Yang, Meng-Ling, et al.
Publicado: (2021)

SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer
por: Sun, Tianshui, et al.
Publicado: (2020)

SLC15A4 Serves as a Novel Prognostic Biomarker and Target for Lung Adenocarcinoma
por: Huang, Hui, et al.
Publicado: (2021)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature
por: Zhang, Simeng, et al.
Publicado: (2021)

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature
por: Bao, Xuanwen, et al.
Publicado: (2019)

Identification of a Hypoxia-Angiogenesis lncRNA Signature Participating in Immunosuppression in Gastric Cancer
por: Wang, Zicheng, et al.
Publicado: (2022)

Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature
por: Zhang, Pengpeng, et al.
Publicado: (2023)

Comprehensive analysis of pyroptosis‐related gene signatures for glioblastoma immune microenvironment and target therapy
por: Wang, Zeyu, et al.
Publicado: (2023)

Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma
por: Feng, Chenzhao, et al.
Publicado: (2022)

Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer
por: Greene, John, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jp9svp336aucrqeb7npnan2j52